TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk patient groups for studies of isomyosamine, aimed at preserving muscle mass during GLP-1 treatment. The partnership analyzes data from 30,000 patients to optimize recruitment and accelerate isomyosamine drug development. Renova’s platform identifies patient subsets based on underlying conditions, acute events, and medication profiles.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA: